Periodic fever syndrome is when a child has recurrent episodes of fever. It is a group of disorders and is a genetic condition. Each episode of fever is known to last for the same amount of time. Aphthous stomatitis, periodic fever, pharyngitis, and adenitis are the most common types of periodic fever syndrome noticed in children. The diagnosis of periodic fever is based on a physical exam by a rheumatologist. A blood test, genetic test, and a review of the family medical history of the child might be essential. The major symptoms presented with periodic fever syndrome include rash, sores in the mouth, abdominal pain, and joint pain. Other symptoms may occur but they are consistent from episode to episode in a child.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the periodic fever syndrome market.
Top Impacting Factors
Increase in government initiatives aimed to raise public awareness regarding rare disorders such as periodic fever syndrome is aiding the industry growth
Rise in research activities and rapid technological advancements are leading to the development of new drugs, improved diagnostic facilities, and therapies, which notably contribute toward the growth of the market. New drug approvals for the treatment of periodic fever syndrome are expected to have a positive impact on the industry.
Drugs that inhibit tumor necrosis factors and interleukins in the immune system are being launched in the market; this can elicit further growth of the periodic fever market.
Other than this, in developed countries, upsurge in investments from the government in the development of advanced healthcare infrastructure will further aid in the market expansion during the forecast period.
Currently, the treatment of this syndrome is carried out with the help of oral anti-inflammatory drugs such as non-steroidal anti-inflammatory drugs and corticosteroids, which help to control the symptoms of the disease but are unlikely to assist in the disease elimination. However, availability of limited treatment options and limited knowledge for periodic fever syndrome hamper the growth of the market, globally.
Market Trends
Researchers at the National Human Genome Research Institute have discovered clues to the causes of non-contagious, recurring fevers and sores that affect children. Several genes have been implicated in the periodic fever syndrome, which could lead to the development of new treatments. Owing to the nature of periodic fever syndrome, researchers have long thought that the answers may lie in genomics.
Currently, drugs that affect the immune system by inhibiting interleukins and tumor necrosis factors are gaining high traction in the market. They are often used to treat different symptoms of periodic fever syndrome. The companies that manufacture these drugs are Wyeth Ltd. (Enbrel) and AbbVie, Inc. (Humira).
However, copycat versions of tumor necrosis factor (TNF) inhibitors from Novartis, Inc. and Amgen, Inc. are now available in the EU market; this is because the patent protection for AbbVie’s Humira has come to an end in Europe.
In addition, NHS England’s Commercial Medicines Unit (CMU) is coordinating a procurement process for adalimumab with the aim of saving money.
Key Benefits of the Report
- This study presents the analytical depiction of the periodic fever syndrome industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the periodic fever syndrome market share.
- The current market is quantitatively analyzed to highlight the periodic fever syndrome market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Periodic Fever Syndrome Report
- Which are the leading players active in the periodic fever syndrome market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the periodic fever syndrome market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is "periodic fever syndrome"?
- What is the "periodic fever syndrome" market prediction in the future?
- What are the current trends and predicted trends?
Periodic Fever Syndrome Market, by Type Report Highlights
| Aspects | Details |
 By Type |
|
 By Treatment |
|
 By Routes of Administration |
|
 By End-Users |
|
 By DISTRIBUTION CHANNEL |
|
 By Region |
|
 Key Market Players | Horizon Therapeutics PLC, Amneal Pharmaceuticals LLC, Texas Allergy Group, PLLC, Novartis AG, Zydus Cadila, Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Co. Ltd., Merck & Co., Inc., Simvastatin, Regeneron Pharmaceuticals, Inc. |
Loading Table Of Content...
